Chemistry: molecular biology and microbiology – Kit
Reexamination Certificate
2005-10-21
2008-11-18
Campell, Bruce (Department: 1648)
Chemistry: molecular biology and microbiology
Kit
C424S093100, C424S215100, C435S320100
Reexamination Certificate
active
07452723
ABSTRACT:
The present invention pertains to methods for preventing reovirus recognition in the treatment of cellular proliferative disorders, and particularly ras-mediated cellular proliferative disorders, in mammals. The method comprises suppressing or otherwise inhibiting the immune system of the mammal and, concurrently or subsequently, administering to the proliferating cells an effective amount of one or more reoviruses under conditions which result in substantial lysis of the proliferating cells. The methods may include the selective removal of immune constituents that may interfere with the systemic delivery of the virus; preventing reovirus recognition by the host immune system; and removal of the virus from an immune suppressed or immune incompetent host following treatment with reovirus. Alternatively, reovirus may be administered to a mammal with a diminished immune response system under conditions which result in substantial lysis of the proliferating cells.
REFERENCES:
patent: 4108983 (1978-08-01), Wallack
patent: 5023252 (1991-06-01), Hseih
patent: 6136307 (2000-10-01), Lee et al.
patent: 6565831 (2003-05-01), Coffey et al.
patent: 0 453 242 (1991-10-01), None
patent: 0 514 603 (1992-11-01), None
patent: WO 90/09441 (1990-08-01), None
patent: WO 90/11765 (1990-10-01), None
patent: WO 94/18992 (1994-09-01), None
patent: WO 97/04805 (1997-02-01), None
patent: WO 97/16443 (1997-05-01), None
patent: WO 97/45142 (1997-12-01), None
patent: WO 98/08541 (1998-03-01), None
patent: WO 99/08692 (1999-02-01), None
patent: WO 99/18799 (1999-04-01), None
patent: WO 00/20041 (2000-04-01), None
patent: WO 01/17537 (2001-03-01), None
Norman et al. J. Clin. Invest. Apr. 15, 2000, vol. 105 (8), pp. 1035-1037.
Ikeda et al. Nature Medicine, Aug. 1999, vol. 5, No. 8, pp. 881-887.
Andreansky, S.S., et al. (1996). The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors. Proc Natl Acad Sci USA. 93(21):11313-11318.
Armstrong, G.D., et al. (1984). Studies on reovirus receptors of L cells: virus binding characteristics and comparison with reovirus receptors of erythrocytes. Virology. 138(1):37-48.
Aronheim, A., et al. (1994). Membrane targeting of the nucelotide exchange factor Sos is sufficient for activating the Ras signaling pathway. Cell. 78(6):949-961.
Avruch, J., et al. (1994). Raf meets Ras: completing the framework of a signal transduction pathway. Trends Biochem Sci. 19(7):279-283.
Baldari, C.T., et al. (1992). Interleukin-2 promoter activation in T-cells expressing activated Ha-ras. J Biol Chem. 267(7):4289-4291.
Barbacid, M. (1987). Ras genes. Annu Rev Biochem. 56:779-827.
Berrozpe, G., et al. (1994). Comparative analysis of mutations in the p53 and K-ras genes in pancreatic cancer. Int J Cancer. 58(2):185-191.
Bischoff, J.R., and Samuel, C.E. (1989). Mechanism of interferon action. Activation of the human P1/eIF-2 α protein kinase by individual reovirus s-class mRNAs: s1 mRNA is a potent activator relative to s4 mRNA. Virology. 172(1):106-115.
Bollag, G., et al. (1996). Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet. 12(2):144-148.
Bos, J.L. (1989). Ras oncogenes in human cancer: a review. Cancer Res. 49(17):4682-4689.
Boviatsis, E.J., et al. (1994). Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase. Gene Ther. 1(5):323-331.
Bryson, J.S., and Cox, D.C. (1988). Characteristics of reovirus-mediated chemoimmunotherapy of murine L1210 leukemia. Cancer Immunol Immunother. 26(2):132-138.
Cahill, M.A., et al. (1996). Signalling pathways: jack of all cascades. Curr Biol. 6(1):16-19.
Coffey, M.C., et al. (1998). Reovirus therapy of tumors with activated Ras pathway. Science. 282(5392):1332-1334.
Chambers, R., et al. (1995). Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma. Proc Natl Acad Sci USA. 92(5):1411-1415.
Chandran, K., and Nibert, N.L. (1998). Protease cleavage of reovirus capsid protein μl/μlC is blocked by alkyl sulfate detergents, yielding a new type of infectious subvirion particle. J Virol. 72(1):467-475.
Chaubert, P., et al. (1994). K-ras mutations and p53 alterations in neoplastic and nonneoplastic lesions associated with longstanding ulcerative colitis. Am J Pathol. 144(4):767-775.
Cuff, C.F., et al. (1998). Enteric reovirus infection as a probe to study immunotoxicity of the gastrointestinal tract. Toxicol Sci. 42(2):99-108.
Der, S.D., et al. (1997). A double-stranded RNA-activated protein kinase-dependent pathway mediating stress-induced apoptosis. Proc Natl Acad Sci USA. 94(7):3279-3283.
Dudley, D.T., et al. (1995). A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA. 92(17):7686-7689.
Duncan, R., et al. (1991). Conformational and functional analysis of the C-terminal globular head of the reovirus cell attachment protein. Virology. 182(2):810-819.
Duncan, M.R., et al. (1978). Differential sensitivity of normal and transformed human cells to reovirus infection. J Virol. 28(2):444-449.
Gale, Jr., M.J., et al. (1997). Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology. 230(2):217-227.
Gentsch, J.R., and Pacitti, A.F. (1985). Effect of neuraminidase treatment of cells and effect of soluble glycoproteins on type 3 reovirus attachment to murine L cells. J Virol. 56(2):356-364.
Gura, T. (1997). Systems for identifying new drugs are often faulty. Science. 278(5340):1041-1042.
Hall-Jackson, C.A., et al. (1998). Induction of cell death by stimulation of protein kinase C in human epithelial cells expressing a mutant ras oncogene: a potential therapeutic target. Br J Cancer. 78(5):641-651.
Hashiro, G., et al. (1977). The preferential cytotoxicity of reovirus for certain transformed cell lines. Arch Virol. 54(4):307-315.
He, B., et al. (1997). Suppression of the phenotype ofγ134.5−herpes simplex virus 1: failure of activated RNA-dependent protein kinase to shut off protein synthesis is associated with a deletion in the domain of the α47 gene. J Virol. 71(8):6049-6054.
Helbing, C.C., et al. (1997). A novel candidate tumor suppressor,ING1, is involved in the regulation of apoptosis. Cancer Res. 57(7):1255-1258.
Hershey, J.W. (1991). Translational control in mammalian cells. Annu Rev Biochem. 60:717-755.
Hu, Y., and Conway, T.W. (1993). 2-Aminopurine inhibits the double-stranded RNA-dependent protein kinase both vitro and vivo. J Interferon Res. 13(5):323-328.
Ikeda, K., et al. (1999). Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med. 5(8):881-887.
Ikeda, K., et al. (2000). Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant. J Virol. 74(10):4765-4775.
Janes, P.W., et al. (1994). Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2. Oncogene. 9(12):3601-3608.
Kawagishi-Kobayashi, M., et al. (1997). Regulation of the protein kinase PKR by the vaccinia virus pseudosubstrate inhibitor K3L is dependent on residues conserved between the K3L protein and the PKR substrate eIF2α. Mol Cell Biol. 17(7):4146-4158.
Kirn, D.H., and McCormick, F. (1996). Replicating viruses as selective cancer therapeutics. Mol Med Today. 2(12):519-527.
Kollmorgen, G.M., et al. (1976). Immunotherapy of EL4 lymphoma with reovirus. Cancer Immunol. Immunother. 1:239-244.
Laemmli, U.K. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227(5259):680-685.
Lee, J.M., and Bernstein, A. (1993). p53 mutations increase resistance to ionizing radiation. Proc Natl Acad Sci USA. 90(12):5742-5746.
Lee, P.W., et al. (1981). Characterization of anti-r
Coffey Matthew C.
Thompson Bradley G.
Campell Bruce
Fish & Richardson P.C.
Li Bao Qun
Oncolytics Biotech Inc.
LandOfFree
Methods for preventing reovirus recognition for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for preventing reovirus recognition for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for preventing reovirus recognition for the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4045463